Tesomet Receives Orphan Drug Status for Hypothalamic Obesity
Tesomet is an investigational fixed-dose combination therapy of tesofensine, a triple monoamine reuptake inhibitor, and metoprolol, a beta-1 selective blocker.
Metabolic Disorders
Bylvay Approved for Progressive Familial Intrahepatic Cholestasis
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.
Major Cardiovascular Events Linked to Metabolic Acidosis
Cardiovascular events are the leading cause of death among patients with chronic kidney disease, and metabolic acidosis in this population is underdiagnosed.
FDA to Review Vutrisiran for Polyneuropathy of Hereditary ATTR Amyloidosis
Vutrisiran is an investigational, subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein.
FDA: More Data Needed to Support Arimoclomol in Niemann-Pick Disease Type C
Arimoclomol is an investigational oral drug candidate that is designed to amplify and sustain the cellular production of heat shock proteins.
Wegovy Approved for Chronic Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist.
Rosuvastatin Reduces Inflammatory Markers in People With HIV and Metabolic Syndrome
Study authors assessed the effect of statins in patients with HIV and metabolic syndrome, as they are usually associated with systemic inflammation and higher cardiovascular risk.
Not All Food Sources of Fructose-Containing Sugars Raise Risk for MetS
The adverse association of sugar-sweetened beverages and incident MetS does not extend to other major food sources of fructose-containing sugars, and yogurt, fruit, 100% fruit juice, and mixed fruit juice all have a protective association with MetS.
Metabolic Syndrome May Up Risk for VTE Recurrence After DVT
For patients with deep vein thrombosis (DVT), the presence of any component of metabolic syndrome (MetS) is independently associated with an increased risk for venous thromboembolism (VTE) recurrence.
Experts Say Endocrine-Disrupting Chemicals Pose Global Health Threat
In an editorial published in Endocrinology, a journal of The Endocrine Society, endocrine experts agreed that endocrine-disrupting chemicals (EDCs) pose a threat to human health and to the ecosystems of the earth. The editorial comes in response to a commentary (Dietrich et al. Chem Biol Interact) signed by a number of editors of toxicology journals that dismisses the state-of-the-science on EDCs and argues for the status quo in the regulation of these hazardous substances.
- Loading...
Loading...
Next post in Medicine Abroad
Loading... 
Loading...